phenylpiperazine has been researched along with Dementia Praecox in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alves, FR; Antonio, CB; Barreiro, EJ; Figueiredo, CD; Fraga, CA; Herzfeldt, V; Moura, BC; Noël, F; Pompeu, TE; Rates, SM | 1 |
| Antonio, CB; Barreiro, EJ; Fraga, CA; Grazziottin, LR; Menegatti, R; Neves, G; Noël, F; Rates, SM; Vieira, RO | 1 |
2 other study(ies) available for phenylpiperazine and Dementia Praecox
| Article | Year |
|---|---|
Synthesis and pharmacological evaluation of new N-phenylpiperazine derivatives designed as homologues of the antipsychotic lead compound LASSBio-579.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Chemistry Techniques, Synthetic; Dose-Response Relationship, Drug; Drug Design; Locomotion; Male; Mice; Piperazines; Receptor, Serotonin, 5-HT2A; Schizophrenia | 2013 |
Searching for multi-target antipsychotics: Discovery of orally active heterocyclic N-phenylpiperazine ligands of D2-like and 5-HT1A receptors.
Topics: Administration, Oral; Animals; Antipsychotic Agents; Cell Line; Humans; Ligands; Male; Mice; Piperazines; Pyrazoles; Rats; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine D2; Schizophrenia | 2010 |